Gaudium IVF and Women Health reported a strong FY26 with revenue rising 47.56% to ₹104.36 crore and PAT growing 27.69% to ₹24.49 crore. The company is actively expanding its footprint with 19 new IVF hubs planned, including a new facility in Delhi. While operational growth remains robust, shareholders should monitor ongoing tax litigation and an arbitration claim involving ₹29.21 crore as the company scales its infrastructure and integrates AI-driven clinical tools.
Gaudium IVF Reports FY26 Revenue of ₹104.36 Crore
Revenue grew 47.56% to ₹104.36 crore in FY26, with PAT rising 27.69% to ₹24.49 crore.
Reader Takeaway: Strong revenue growth driven by expansion, though investors should weigh legal risks against operational scale-up costs.
What just happened
Gaudium IVF and Women Health Ltd announced its financial performance for FY26, highlighting a 47.56% surge in consolidated revenue to ₹104.36 crore. The company’s PAT reached ₹24.49 crore, with an EBITDA margin of 36.13%. Management noted that margin moderation during the period was largely due to front-loaded costs associated with scaling operations and a shift in the revenue mix toward lower-margin pharmacy services.
Why this matters
The company is aggressively reinvesting capital raised during its February 2026 IPO to expand its national footprint. The roadmap includes 19 new IVF hubs by FY29, with the first of these already operational in South Extension, Delhi. Furthermore, a ₹15 crore investment has been approved for a specialized women’s hospital in Lucknow, signaling a long-term capital commitment to infrastructure.
Technology Integration
Innovation remains a core growth pillar. In April 2026, Gaudium integrated AI-based tools, including the Sperm Identification Device and the Embryo Ranking Intelligent Classification Assistant, into clinical practices. Early data from these deployments suggests an 8% improvement in success rates for first-attempt IVF cycles.
Risks to watch
Investors should stay alert to two significant legal matters: an arbitration claim from Neomile Corporate Advisory Limited for ₹29.21 crore and outstanding tax demands totaling ₹34.19 crore. While management maintains that the arbitration claim lacks merit, both matters remain pending and require oversight.
What to track next
The 11th Annual General Meeting, scheduled for September 28, 2026, will be a key event for shareholders, particularly regarding proposed changes to director remuneration and official ratification of management compensation packages.